News

Chimeric antigen receptor (CAR) T-cell therapy has been shown to improve health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma (LBCL). Currently, CAR T-cell therapies are primarily administered in inpatient settings. In a study published in JAMA Network Open, researchers found CAR T-cell therapy administered to patients with relapsed or refractory LBCL in outpatient settings was associated with lower estimated overall costs.

During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts discussed several novel treatments that are changing the relapsed/refractory mantle cell lymphoma treatment landscape, including Bruton tyrosine kinase (BTK) inhibitors, BTK combinations, and chimeric antigen receptor T-cell therapy.

Nina Shah, MD, highlights some of the recent advances that have been made with CAR T-cell therapy in multiple myeloma, as well as other exciting updates in the space.

Bob Valamehr, PhD, discusses the process by which a targeted CAR natural-killer cell product is engineered as well as how it will be examined in future research efforts.

Investigators at Montefiore showed that axicabtagene-ciloleucel can be used successfully in ethnically diverse patients with high-risk, relapsed/refractory diffuse large B-cell lymphoma at an inner-city hospital.

Jyoti D. Patel, MD and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.

Mount Sinai Health System announced that they will be using the allogeneic stem cell therapy remestemcel-L in patients with COVID-19, and have already tested the therapy in 10 patients.

Dylan Essner, discusses the utility of novel electronic documentation tools developed by technicians at Epic Beacon, among others, in the documentation, grading, and treatment of patients receiving CAR T-cell therapy.

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, June 2, 2020 at 8 PM EST.

Investigators trying to find a way to stop antigen loss following CD19 CAR T cell therapy found an approach simultaneously targeting CD19 and CD22 is safe and feasible.

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, May 19, 2020 at 8 PM EST.

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, May 19, 2020 at 8 PM EST.

Researchers found that the potential availability of CAR T-cell therapies for large B-cell lymphomas with lower adverse event rates that are suitable for outpatient administration may reduce the total costs of care.

A review of the role of immune therapy in HPV-associated head and neck squamous cell carcinoma, along with the evidence and perspective behind differing therapeutic considerations.

Michael Wang, MD, discusses the implications of the ZUMA-2 trial for patients with relapsed/refractory mantle cell lymphoma and other targeted therapies on the horizon.

Findings from the pivotal phase II ZUMA-2 trial of KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma were published in the New England Journal of Medicine, as the FDA considers a biologics license application for the CAR T-cell therapy for an approval in this setting.

The FDA cleared the investigational new drug (IND) application for the use of CYNK-001 in adults with COVID-19.

Mantle cell lymphoma is a type of B-cell non-Hodgkin lymphoma with a typically poor prognosis. Even with an allogeneic stem cell transplant, patients can become resistant to chemotherapy. Most do not survive 4 or 5 years after diagnosis, and the 10-year survival rate hovers between 5% and 10%.

Carlos R. Bachier, MD, discusses the use of CAR T-cell therapy in the outpatient setting. He also shared insight on the evolving paradigm of graft-versus-host disease.

Tania Jain, MBBS, discusses blood count recovery in patients with hematology malignancies who receive CAR T-cell therapy.

Sameer Desai, MD, discusses his experience in the hematology field and how CAR T-cell therapy has evolved and its potential integration into community centers.

Preliminary data from the ASPIRO study of Audentes Therapeutics resamirigene bilparvovec gene therapy suggests it is safe with improvements in neuromuscular and respiratory function.

Craig Sauter, MD, discusses results of a retrospective, real-world review of patients with hematologic malignancies who developed cytopenia post-CAR T-cell therapy.

Nearly all patients in this cohort achieved a clinically meaningful >3-point increase during the study period, demonstrating a consistent response to the gene therapy.

Gregory A. Otterson, MD, discusses the utility of immunotherapy in squamous non–small cell lung cancer and targeted the evolution of targeted therapy in biomarker-driven disease.

Himisha Beltran, MD, discusses research evaluating cell-free DNA to identify therapy resistance in prostate cancer.

David P. Carbone, MD, PhD, discusses advances in immunotherapy and targeted therapy in non–small cell lung cancer and ongoing research efforts focused on acquired resistance to available therapies.

The Chinese National Medical Products Administration has approved almonertinib (Ameile; HS-10296) for the treatment of patients with EGFR T790M mutation–positive non–small cell lung cancer who have progressed on or after other EGFR TKI therapy.